Akebia Therapeutics
Markets kidney-disease medicines while advancing rare-renal and HIF programs.
$0.8897
After-hours close+0.01 (+1.13%)
At close$0.8798(−6.38%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.03 | — | — |
| Aug 2026 | −$0.04 | −$0.02 | +52.4% |
| May 2026 | −$0.01 | −$0.03 | −200.0% |
| Feb 2026 | −$0.03 | −$0.05 | −66.7% |
| Nov 2025 | −$0.06 | $0.00 | +103.3% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 9, 2026 | −$0.03 | — | — | $46.5M | — | — |
| Aug 5, 2026 | −$0.04 | −$0.02 | +52.4% | $48.9M | $49.1M | +0.6% |
| May 7, 2026 | −$0.01 | −$0.03 | −200.0% | $51.7M | $53.5M | +3.6% |
| Feb 26, 2026 | −$0.03 | −$0.05 | −66.7% | $46.1M | $57.6M | +25.0% |
| Nov 10, 2025 | −$0.06 | $0.00 | +103.3% | $48.4M | $58.8M | +21.5% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Aug 7, 2025 | ||||||
| May 8, 2025 | ||||||
| Mar 13, 2025 | ||||||
| Nov 7, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 9, 2024 | ||||||
| Mar 14, 2024 | ||||||
| Nov 8, 2023 | ||||||
| Aug 25, 2023 | ||||||
| May 8, 2023 | ||||||
| Mar 9, 2023 | ||||||
| Nov 3, 2022 | ||||||
| Aug 4, 2022 | ||||||
| May 9, 2022 | ||||||
| Mar 1, 2022 | ||||||
| Nov 4, 2021 | ||||||
| Aug 5, 2021 | ||||||
| May 10, 2021 | ||||||
| Feb 25, 2021 | ||||||
| Nov 5, 2020 | ||||||
| Aug 10, 2020 | ||||||
| May 5, 2020 | ||||||
| Mar 10, 2020 | ||||||
| Nov 12, 2019 | ||||||
| Aug 8, 2019 | ||||||
| May 9, 2019 | ||||||
| Mar 26, 2019 | ||||||
| Nov 8, 2018 | ||||||
| Aug 8, 2018 | ||||||
| May 9, 2018 | ||||||
| Mar 12, 2018 | ||||||
| Nov 8, 2017 | ||||||
| Aug 8, 2017 | ||||||
| May 9, 2017 | ||||||
| Mar 6, 2017 | ||||||
| Nov 9, 2016 | ||||||
| Aug 8, 2016 | ||||||
| May 5, 2016 | ||||||
| Mar 14, 2016 | ||||||
| Nov 9, 2015 | ||||||
| Aug 11, 2015 | ||||||